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proved in the ASV group compared to the control group 
(–39 ± 18 vs. –0.2 ± 13.2/h, p < 0.001). At baseline, 24 (75%) 
patients had impaired LV relaxation, and 8 (25%) had a pseu-
do-normalized filling pattern. At the 12-week control visit, 
diastolic function assessed by the isovolumetric relaxation 
time (–10.3 ± 26.1 vs. 9.3 ± 49.1, p = 0.48) and deceleration 
time (–43.9 ± 88.8 vs. 12.4 ± 68.8, p = 0.40) tended to improve 
after ASV treatment, but did not reach statistical signifi-
cance. Likewise, the proportion of patients whose diastolic 
dysfunction improved was nonsignificantly higher in the 
ASV than in the control group, respectively (37 vs. 15%, p = 
0.25).  Conclusions: ASV treatment efficiently abolishes SDB 
in patients with stable systolic HF and concomitant diastolic 
dysfunction, and was associated with a statistically nonsig-
nificant improvement in measures of diastolic dysfunction. 
Thus, these data provide estimates of effect size and justify 
the evaluation of the effects of ASV on diastolic function in 
larger randomized controlled trials. 
Copyright  © 2013 S. Karger AG, Basel 
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 Abstract 
 Background: Systolic heart failure (HF) is frequently accom-
panied by diastolic dysfunction and sleep-disordered 
breathing (SDB).  Objectives: The objective of this subset 
analysis was to determine effect sizes of auto-servo ventila-
tion (ASV and biphasic positive airway pressure ASV) on 
echocardiographic measures of diastolic function in patients 
with systolic HF and SDB.  Methods: Thirty-two patients with 
stable systolic HF, concomitant diastolic dysfunction [age 
66 ± 9 years old, left ventricular (LV) ejection fraction: 30 ± 
7% and New York Heart Association class II: 72%] and SDB 
(apnea-hypopnea index, AHI: 48 ± 19/h; 53% had predomi-
nantly obstructive sleep apnea) receiving either ASV (n = 19) 
or optimal medical treatment (control, n = 13) were analyzed 
in a randomized controlled clinical trial. Polysomnographic 
and echocardiographic measurements were obtained at 
baseline and after 12 weeks.  Results: AHI significantly im-
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 Introduction 
 Heart failure (HF), affecting about 1–2% of individuals 
in the Western World with increasing prevalence with 
increasing age, is still associated with high morbidity and 
mortality  [1] . Systolic left ventricular (LV) impairment, a 
hallmark of HF with reduced ejection fraction (HFREF), 
is often accompanied by diastolic dysfunction, which has 
been shown to represent an independent prognostic fac-
tor for a worse outcome – even in patients with concom-
itant systolic dysfunction  [2–4] . Beyond that, accumulat-
ing evidence links HFREF to sleep-disordered breathing 
(SDB) as further concomitant entity, affecting about 51–
76% of patients with HFREF  [5–7] .
 Current pathophysiological concepts indicate that both 
HFREF and SDB stand in a reciprocal relationship with 
each other. While impaired cardiac function can cause and 
aggravate SDB  [8] , SDB may contribute to worsening of 
HFREF by increasing cardiac afterload, causing hyperten-
sion and myocardial hypertrophy  [6, 9–14] .
 In this context, facing the somehow stagnating thera-
peutic options in HFREF treatment  [15] , it has been hy-
pothesized that an SDB-specific therapy might also be ef-
fective in improving parameters of cardiac dysfunction. 
In HF patients with impaired systolic function, there is 
robust evidence that continuous positive airway pressure 
(CPAP) modestly increases LV ejection fraction (LVEF). 
However, current evidence in such patients is conflicting 
with studies of auto-servo ventilation (ASV) showing a 
modest improvement in LVEF  [16] , whereas others did 
not  [17, 18] .
 Furthermore, the effects of positive airway pressure 
treatment on diastolic dysfunction have not been studied 
in detail. A randomized crossover study in patients with 
SDB without evidence of HF showed that CPAP mod-
estly improves echocardiographic parameters of diastolic 
dysfunction  [19] . Another trial investigating ASV thera-
py in patients with SDB and concomitant HF with normal 
EF likewise found a moderate improvement in echocar-
diographic diastolic parameters  [20] . However, there is 
no randomized controlled study evaluating the extent to 
which an SDB-specific therapy might influence diastolic 
dysfunction in patients with HFREF.
 We therefore tested in a subset of patients with HFREF 
and SDB with concomitant diastolic dysfunction from a 
multicenter, randomized, rater-blinded, open label, paral-
lel group trial  [21] to which extent an SDB-specific therapy 
(ASV, biphasic PAP ASV, Philips Respironics) influences 
echocardiographic measures of LV structure and diastolic 
function compared to an optimal medical therapy alone.
 Patients and Methods 
 Patients 
 The patient population analyzed is a subset of the multicenter, 
randomized, rater-blinded, open label, parallel group trial ‘Treat-
ment of Sleep-Disordered Breathing with Auto-Servo Ventilation 
in Congestive Heart Failure’, which has been registered at http://
www.clinicaltrials.gov/ (ISRCTN04353156)  [21] .
 Individuals were eligible to be part of the present analysis if they 
were 18–80 years old, had chronic HF due to ischemic or nonisch-
emic cardiomyopathy, had a LVEF  ≤ 40% on echocardiography, 
were in a stable clinical status (New York Heart Association class 
II or III) with optimal medical treatment according to the guide-
lines of the European Society of Cardiology  [22] for at least 4 weeks 
and had an apnea-hypopnea index (AHI)  ≥ 20/h sleep as assessed 
by in-laboratory polysomnography. Subjects were excluded if they 
had evidence of an unstable clinical status (unstable angina, myo-
cardial infarction, cardiac surgery or hospital admission within the 
previous 3 months), had contraindications to PAP therapy, were 
on oxygen therapy, or had severe restrictive or obstructive airway 
disease. All patients gave written informed consent, and the pro-
tocol was approved by the local ethics boards of the participating 
institutions.
 Eligible patients meeting all inclusion criteria were then as-
signed to either an ASV-treated group receiving ASV in addition 
to an optimal medical treatment for HF or a control group with 
optimal medical treatment alone. Echocardiographic (evaluation 
of systolic/diastolic function and LV diameters), hemodynamic 
(systolic and diastolic blood pressure, BP), neurohumoral [N-ter-
minal (NT)-pro-B-type natriuretic peptide (BNP)] and SDB pa-
rameters (AHI) were determined at baseline and after 12 weeks, 
respectively.
 Additional inclusion criteria for the present analysis were that 
echocardiographic parameters of diastolic dysfunction were avail-
able and that individuals fulfilled echocardiographic criteria for 
diastolic dysfunction (classified as either impaired relaxation, or 
pseudo-normal or restrictive filling pattern). These additional cri-
teria applied to 44% of the initially included study cohort repre-
senting all subjects with a complete echocardiographic evaluation 
of diastolic dysfunction, which has been performed in two of four 
study centers (see  fig. 1 for patient flow).
 Initiation of ASV 
 By protocol, nighttime pressure settings had to be within the 
range of tolerated pressure settings during an attended daytime 
titration with monitoring of BP and heart rate (HR). During the 
first night, CPAP was titrated under polysomnographic monitor-
ing from 4 cm H 2 O in 1-cm H 2 O increments to the point where 
any sign of flow limitation was eliminated or the maximum level 
the patient could tolerate ( ≤ 10 cm H 2 O).
 Before initiating ASV at night, a daytime titration with bilevel 
PAP was performed in order to avoid long-term application of 
ASV with pressure settings that may lead to hemodynamic com-
promise. First baseline BP and HR were recorded as described. 
Expiratory PAP was set at the optimal CPAP level suppressing up-
per airway obstruction determined by polysomnography. Inspira-
tory pressure support was titrated starting from 1 cm H 2 O and 
increased by 1-cm H 2 O up to the maximum of 10 cm H 2 O every 
5 min after BP and HR reading was taken. Attended daytime in-
spiratory pressure support titration was stopped when a pressure 
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of 10 cm H 2 O was reached or if mean BP <60 mm Hg or a drop of 
>15 mm Hg occurred or the patient did not tolerate inspiratory 
pressure support.
 At the ASV initiation night, the expiratory PAP of the ASV de-
vice was set to the CPAP determined during the titration night. 
The minimum inspiratory PAP was set to the expiratory PAP lev-
el, and the maximum inspiratory PAP to a maximum of 10 cm H 2 O 
above the expiratory PAP level, or not higher than the maximum 
the patient could tolerate during the daytime test. The default 
backup rate of the machine was used. Assessment of hours of ASV 
use over this period were obtained from the downloadable Smart-
Card located in the device.
 Echocardiography 
 Transthoracic echocardiography was performed with pa-
tients in the supine and left-lateral positions using high-quality 
echocardiographs. Images were obtained in the parasternal 
long- and short-axis, apical 2- and 4-chamber, and subcostal 
views with 2D, M-mode and Doppler echocardiography. Inves-
tigators were experienced echocardiographers, and each echo-
cardiogram was centralized to two blinded analysts. Left atrial 
diameter, LV end-diastolic and end-systolic diameters, as well as 
interventricular septum thickness and LV posterior wall thick-
ness were determined in accordance with the recommendations 
of the American Society of Echocardiography  [23] . LV systolic 
function was assessed by LVEF obtained by the Simpson‘s meth-
od (LV end-diastolic volume minus LV end-systolic volume di-
vided by end-diastolic volume). LV mass (LVM) was calculated 
from M-mode echocardiograms according to the formula de-
scribed by Devereux et al.  [24] , and LVM index (LVMI) was ob-
tained by indexing LVM to body surface area. Relative wall 
thickness was determined by the formula (2 × PWTd)/LVIDd, 
where PWTd is posterior wall thickness at end-diastole and 
LVIDd is end-diastolic ventricular internal dimension at end-
diastole  [23] .
 LV diastolic function was assessed by measuring the mitral in-
flow pattern (with the sample volume placed between the leaflet 
tips using pulsed-wave Doppler technique), the deceleration time 
(DT) and the isovolumetric relaxation time (IVRT). Peak flow ve-
locity in early diastole (E wave) was divided by the peak velocity at 
atrial contraction (A wave) resulting in the E/A ratio. LV filling 
patterns were then classified as normal, impaired relaxation, pseu-
do-normal or restrictive. A normal pattern was defined by E/A 
ratio >1, and normal DT (<220 ms) and IVRT (<100 ms). Impaired 
relaxation was identified by E/A ratio <1, DT >220 ms and IVRT 
>100 ms. A pseudo-normal pattern was determined by E/A ratio 
ranging from 1 to 1.5, DT <150 ms and IVRT <60 ms, and a restric-
tive pattern was defined by E/A ratio >1.5, DT <150 ms and IVRT 
<60 ms  [25] .
 Statistical Analysis 
 Values are expressed as means ± SD or percentages. Baseline 
characteristics of the patients in the two groups were compared 
using the nonparametric Wilcoxon-Mann-Whitney test. To take 
into account potential differences in baseline rates between the 
two groups, we used a generalized linear model based on ranks 
(nonparametric) with the respective baseline value as covariate. All 
statistical tests were two sided with a significance level of 5%. All 
statistical tests were performed with SPSS 20.0.
 Results 
 Patient Characteristics  
 In the initial study cohort (participating patients with 
complete assessment of diastolic function;  fig.  1 ), the 
prevalence of diastolic dysfunction was very high (86 and 
93% in the treatment and control group, respectively).
72 excluded
 67 not meeting inclusion
 criteria
 5 declined to participate
37 ASV group
 37 received allocated intervention
19 included in analysis 13 included in analysis
18 excluded from analysis
 4 withdrew
 1 deceased (pneumonia)
 3 no diastolic dysfunction
 10 no diastolic parameters
144 assessed for eligibility
72 randomized
35 control group
 34 received allocated intervention
 1 received ASV intervention
21 excluded from analysis
 4 withdrew
 1 no diastolic dysfunction
 16 no diastolic parameters
 Fig. 1. Study protocol.  
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 Patients with diastolic dysfunction were predomi-
nantly normotensive males with both ischemic and non-
ischemic systolic HF (mainly New York Heart Associa-
tion class II congestive HF severity) and concomitant 
 obstructive or central sleep apnea indicated by a patho-
logical AHI. Medical therapy was sufficient according to 
current guidelines with a high percentage of patients 
treated with β-blockers, angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers, and spirono-
lactone.  Table 1 shows the proportion of patients using 
cardiac medication, which did not change significantly 
during the follow-up period: in 1 patient from the control 
group, a β-blocker was added, and in 2 patients from the 
ASV group spironolactone was discontinued.
 There were no statistically significant differences be-
tween both groups in demographic, hemodynamic, echo-
cardiographic or SDB parameters.
 SDB Parameters 
 At baseline, AHI was 51.7 ± 18.9 events/h in the ASV-
allocated group and 43.1 ± 18.4 events/h in the control 
group (p = 0.33). After 12 weeks of ASV treatment, AHI 
was significantly reduced to 11.2 ± 7.2 events/h, whereas 
it remained unchanged in the control group (p < 0.001 
ASV vs. control;  table 2 ). The average daily ASV use dur-
ing the study period was 4.2 ± 2.7 h.
 Hemodynamic, Neurohumoral and Functional LV 
Parameters  
 Individuals of both groups were normotensive at base-
line, and neither systolic nor diastolic BP did vary signif-
icantly after 12 weeks ( table 2 ). Likewise, NT-pro-BNP 
levels were similar in both groups at baseline, showing no 
significant difference after 12 weeks ( table 2 ). Baseline LV 
systolic function measured by LVEF was 30 ± 8% in the 
ASV group and 29 ± 7% in the control group (p = 0.66). 
After 12 weeks, the change in LVEF was similar in the 
ASV-treated and control groups (p = 0.75,  table 2 ).
 LV Structural Parameters 
 LV structural parameters were largely unchanged dur-
ing the 12-week follow-up of both the ASV and the con-
trol group. Relative wall thickness was unchanged in the 
treatment group but tended to increase in control sub-
jects.
 Parameters of Diastolic LV Dysfunction 
 Severity of diastolic dysfunction was graded according 
to echocardiographic measurements of the E/A ratio, DT 
and IVRT. At baseline, most patients had impaired LV 
relaxation (i.e. grade 1 diastolic dysfunction), and about 
one quarter revealed a pseudo-normal filling pattern 
( fig. 2 a). After 12 weeks, more ASV than control patients 
improved to a normal filling pattern (26 vs. 15%), and less 
ASV than control patients remained in the pseudo-nor-
mal state (11 vs. 23%), even though neither of these ASV-
mediated improvements reached statistical significance 
(p = 0.55;  fig. 2 b). Regarding the individual parameters of 
diastolic dysfunction, the E/A ratio slightly increased in 
both study groups ( fig. 3 a).
 In the ASV group, DT and IVRT were reduced, indi-
cating improvement in diastolic function, while in the 
control group DT remained similar within the follow-up 
period. Between-group differences comparing the change 
in DT and IVRT within 12 weeks were statistically not 
significant (p = 0.40 and p = 0.48, respectively;  table 2 ; 
 figure 3 b, c).
Table 1.  Baseline characteristics of the study patients
ASV Control p value 
Patients, n 19 13
Age, years 66±9 66±11 0.73
Males, n (%) 18 (95) 11 (85) 0.55
Body mass index, kg/m2 29.9±4.0 30.7±3.6 0.58
Smokers, n (%) 2 (11) 3 (23) 0.16
BP, mm Hg
Systolic
Diastolic
120±18
70±14
128±24
75±11
0.40
0.37
Heart rate, b.p.m. 70±10 71±12 0.64
New York Heart Association class, n (%)1 0.35
II
III
12 (63)
5 (26)
11 (85)
1 (8)
LVEF, % 30±8 29±7 0.66
NT-pro-BNP, ng/ml 1,046±1,195 997±1,344 0.33
Cause of HF, n (%)
Ischemic
Nonischemic
9 (47)
10 (53)
6 (46)
7 (54)
0.47
Sleep apnea, n (%)
Obstructive
Central
10 (53)
9 (47)
7 (54)
6 (46)
1.00
AHI, events/h 51.7±18.9 43.1±18.4 0.33
Medication, n (%)
Diuretic
Spironolactone
ACEI
ARB
β-Blocker
11 (58)
9 (47)
15 (79)
4 (21)
16 (84)
11 (85)
8 (62)
9 (69)
5 (38)
13 (100)
0.14
0.49
0.68
0.43
0.25
 ACEI = Angiotensin-converting enzyme inhibitor; ARB = an-
giotensin receptor blocker. 
1 Data of 2 and 1 patients are missing in the ASV and control 
group, respectively.
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 Discussion 
 The main findings of this study evaluating ASV thera-
py in patients with HFREF, diastolic dysfunction and 
SDB are that (1) prevalence of diastolic dysfunction is 
very high in patients with HFREF and SDB; (2) ASV ther-
apy effectively suppresses SDB, and (3) ASV therapy does 
not significantly alter echocardiographic measures of 
LV structure and diastolic dysfunction in this study co-
hort.
Table 2.  Sleep, neurohumoral and echocardiographic parameters and blood pressure in ASV versus control patients at baseline and 
after 12 weeks
ASV  Control p value 
baseline 12 weeks basel ine 12 weeks
Parameter of SDB severity
AHI, events/h 52±19 11±7 43±18 43±19 <0.001
Hemodynamic, neurohumoral and functional LV parameters
Systolic BP, mm Hg 119±18 110±18 128±24 125±19 0.22
Diastolic BP, mm Hg 70±14 70±17 75±11 74±14 0.80
NT-pro-BNP, ng/ml 1,046±1,195 1,163±1,498 997±1,344 1,042±1,312 0.92
LVEF, % 30±8 31±10 29±7 32±9 0.75
LV structural parameters
LVEDD, mm 67±9 67±9 66±7 65±7 0.32
LVESD, mm 55±11 55±12 52±10 50±8 0.31
IVS, mm 11±2 11±2 10±2 10±2 0.41
LVPW, mm 10±2 10±2 10±2 11±2 0.21
Left atrial diameter, mm 48±8 49±7 46±7 50±10 0.37
RWT, % 0.30±0.08 0.30±0.06 0.31±0.06 0.33±0.07 0.09
LVM, g 378±111 371±106 351±96 364±135 0.91
LVMI, g/m2 188±58 183±52 174±42 179±57 0.66
LV diastolic parameters
E wave, m/s 0.63±0.21 0.69±0.30 0.59±0.21 0.63±0.20 0.66
A wave, m/s 0.73±0.27 0.70±0.25 0.73±0.25 0.66±0.28 0.48
E/A ratio 0.99±0.61 1.20±0.99 0.94±0.55 1.25±0.89 0.98
DT, ms 259.0±86.6 212.3±82.4 207.5±55.5 217.7±68.1 0.40
IVRT, ms 117.4±25.8 106.2±25.2 102.9±43.3 107.9±23.1 0.48
 LVEDD = LV end-diastolic diameter; LVESD = LV end-systolic diameter; IVS = interventricular septum thickness; LVPW = LV posterior 
wall thickness; RWT = relative wall thickness. To be able to take potential differences in baseline rates between the two groups into account, a 
generalized linear model based on ranks (nonparametric) with the respective baseline value as covariate was used.
0 0
76.9 73.7
23.1 26.3
0 0
0
10
20
30
40
50
60
70
80
90
100
Normal Impaired
relaxation
Pseudo-
normal
Restrictive
S
u
b
je
ct
s 
(%
)
Baseline
a
0
10
20
30
40
50
60
70
80
90
100
S
u
b
je
ct
s 
(%
)
15.4
26.3
61.5 63.2
23.1
10.5
0 0
Normal Impaired
relaxation
Pseudo-
normal
Restrictive
12 weeks
Control patients
ASV patients
b
 Fig. 2. Grade of diastolic dysfunction at baseline ( a ) and after 12 weeks ( b ) in ASV (gray bars) and control subjects (white bars).  
 Effects of ASV  Respiration 2014;87:54–62 
DOI: 10.1159/000351797
59
 Prevalence of LV Diastolic Dysfunction 
 Diastolic dysfunction was detected in a total of 89% 
of patients with HFREF in the current analysis, which 
is similar to the 82% prevalence reported in larger sam-
ples of HFREF patients from the community  [26] . A 
previous study in patients with normal EF observed a 
close relationship between SDB and diastolic dysfunc-
tion affecting 23  [27] to 56%  [19] of subjects under in-
vestigation with a stepwise further increase as severity 
of SDB rises, ultimately reaching a prevalence of ap-
proximately 70%  [28] . Even though this link between 
SDB and diastolic dysfunction is evident, the underly-
ing pathophysiological mechanisms are still not well 
characterized. It has been hypothesized that both eleva-
tions in nocturnal BP and activation of the sympathet-
ic nervous system might contribute to this effect  [29–
31]  by increasing LV afterload [32]. Furthermore, futile 
inspiratory efforts hallmarking obstructive sleep ap-
nea might increase LV transmural pressure and hence 
afterload by inducing negative intrathoracic pressures 
 [32] , ultimately provoking diastolic dysfunction. Even 
though each of these concepts could plausibly explain 
the impact of SDB on diastolic dysfunction on its own, 
any deterioration in diastolic filling in patients with ad-
vanced complex disease, such as severely impaired car-
diac function, might most likely be caused polyetiolog-
ically.
 Effectiveness of ASV Therapy on SDB Severity and LV 
Systolic Dysfunction 
 In accordance with previous studies, ASV therapy was 
highly efficient in suppressing apnea and hypopnea in pa-
tients with SDB and HF  [16, 17, 33–38] .
 In contrast, LV systolic function determined by EF did 
not significantly improve in ASV-treated patients. On the 
one hand, this is congruent with previous findings, which 
also did not reveal a significant effect of an SDB-specific 
therapy on LVEF in HF patients  [17, 39] but, on the oth-
er hand, it contrasts with studies reporting a positive ef-
fect on systolic function  [16, 36, 38, 40–43] . For instance, 
Bradley et al.  [40] described a rather moderate but sig-
nificant gain of systolic function (LVEF 2.2 ± 5.4 vs. 0.4 ± 
5.3%, p = 0.02) in their study evaluating CPAP versus no 
CPAP in 258 HF patients with central sleep apnea. This 
discrepancy between trials showing positive effects of an 
SDB-specific therapy on LVEF and studies, e.g. ours, 
which could not find such a relationship, could have two 
main reasons. First, improvements in LVEF might de-
pend on the duration of SDB-specific therapy. This is 
supported by the finding that trials with a treatment du-
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ration  ≤ 6 weeks could not show a significant effect of ASV 
on LVEF  [17, 18] , whereas studies with a treatment dura-
tion >6 weeks did  [36, 38] . This time dependency was also 
found in trials evaluating acute versus chronic effects of 
an SDB-specific therapy: so LVEF was even significantly 
reduced after acute initiation of CPAP treatment and 
only improved with ongoing therapy eventually leading 
to a significant gain of LVEF in the longer term  [44, 45] . 
Secondly, since treatment effects on LVEF are generally 
rather low (as seen by a 2.2 ± 5.4% improvement in LVEF 
in the 258 patients evaluated by Bradley et al.  [40] ), the 
cohort size under investigation might also be of relevance, 
and larger cohorts need to be evaluated to finally judge 
the impact of ASV therapy on LVEF.
 Impact of ASV Therapy on Diastolic Dysfunction and 
LV Geometry 
 Our study was the largest one to evaluate echocardio-
graphic parameters of LV diastolic dysfunction in a col-
lective of HFREF patients with concomitant sleep apnea. 
Even though there was no significant overall change in 
diastolic dysfunction, we nevertheless found a modest 
decrease in both DT and IVRT in the ASV-treated group 
with opposite changes in the control group. These mod-
erate alterations translated into more patients in the 
ASV-treated group reaching a normal diastolic function 
with less patients remaining in the state of a pseudo-nor-
mal filling pattern than control patients, respectively. As 
for the systolic LV function, treatment duration might 
again be a determinant of effect size, which means that 
longer treatment periods could eventually unveil more 
distinct changes in LV diastolic function. This is sup-
ported by Bitter et al.  [20] , who evaluated ASV treatment 
in patients with HF and normal EF. In this trial, echocar-
diographic parameters of diastolic dysfunction improved 
after a time period of 11.6 ± 3 months. In contrast, Arias 
et al. [19] , investigating the impact of ASV treatment on 
diastolic function in individuals with obstructive sleep 
apnea, but no concomitant cardiac disease, found an im-
provement in echocardiographic parameters already af-
ter a mean of 104 ± 31 days, with effect sizes which were 
rather similar to the ones found in our study. This in 
mind, it seems plausible that ASV treatment needs to be 
executed the longer the more severely cardiac function is 
impaired to eventually improve also diastolic dysfunc-
tion.
 Patients included in the current analysis displayed a 
pronounced eccentric LV hypertrophy indicated by a rel-
atively low LV wall thickness and a high LVMI. Even 
though it did not reach statistical significance, LVMI 
tended to decrease in the ASV treatment group and to 
further increase in the control group after 12 weeks, re-
spectively.
 Interestingly, it has been shown that LVMI is positive-
ly correlated with the severity of sleep apnea in patients 
with both normal  [46] and impaired systolic LV function 
 [47] . Furthermore, CPAP therapy proved to be efficient 
in reducing LVM in a cohort of patients with normal EF 
 [48] . Sleep apnea seems to further aggravate structural 
LV anomaly even in HFREF patients, and an SDB-specif-
ic therapy has the potential to reverse pathological LV 
remodeling. Against this background, it seems plausi-
ble that subjects suffering from severely impaired cardi-
ac  function, as the ones included in the current analy-
sis,  might need SDB therapy for a longer period than 
12  weeks to more explicitly exhibit reverse cardiac re-
modeling. This is also supported by the work from Colish 
et al.  [48] , who found an ongoing decrease in LVMI even 
after 12 months of CPAP therapy in patients without LV 
systolic dysfunction.
 Regarding other measures of LV geometry, Kaneko et 
al.  [49] observed in a single-center randomized con-
trolled trial of similar sample size in patients with conges-
tive HF and obstructive sleep apnea a significant reduc-
tion of LV end-systolic diameter after 4 weeks of CPAP 
treatment versus control. In the present multicenter 
study in patients with congestive HF on contemporary 
HF therapy with both obstructive and central sleep ap-
nea, ASV therapy had no significant effects on LV diam-
eters.
 Limitations 
 The number of study patients was limited, since this 
subset analysis was conceptually intended as pilot trial to 
provide estimates of effect size to be expected. Otherwise, 
this investigation is the largest one to date which analyzed 
effects of ASV therapy on diastolic dysfunction in HFREF 
patients.
 Furthermore, since randomization of the initial study 
cohort was stratified by study center and type of SDB (i.e. 
central and obstructive sleep apnea), every subset analysis 
might alter this initial randomization and stratification 
scheme. However, the proportion of patients from each 
center included in the present analysis was similar in the 
ASV and control groups, respectively, and the proportion 
of patients with predominantly obstructive sleep apnea 
was similar in the primary analysis  [50] and in the present 
analysis (ASV group: 47 vs. 53%; control group: 52 vs. 
54%). Thus, it is unlikely that the present subgroup anal-
ysis of ASV and control patients significantly altered the 
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original randomization or stratification scheme, leading 
to a false-positive result.
 Finally, there might have been additional confounders 
influencing the effects of ASV therapy on diastolic func-
tion, such as a change in medication or compliance to use 
ASV during the study period. We therefore additional-
ly adjusted for these parameters, which resulted in a sig-
nificant decrease in NT-pro-BNP in the ASV group after 
12 weeks compared to control patients (p = 0.009), where-
as there was no significant alteration in any structural or 
functional (systolic and diastolic) LV parameter (data not 
shown).
 Conclusion 
 The current study revealed a high prevalence of dia-
stolic dysfunction in patients with HFREF and concomi-
tant sleep apnea. It furthermore confirmed the efficiency 
of ASV in reducing apnea-hypopnea events in SDB pa-
tients. Whereas neither systolic nor diastolic parameters 
significantly changed after ASV therapy, there were nev-
ertheless trends towards an improvement in both diastol-
ic function and cardiac remodeling. Thus, these data pro-
vide estimates of effect size and justify the evaluation of 
the effects of ASV on diastolic function in larger random-
ized controlled trials.
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